HeartSciences Inc. (HSCS) Research & Development (2021 - 2026)

HeartSciences (HSCS) has reported Research & Development for 6 consecutive years, with $476205.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 48.75% year-over-year to $476205.0; the trailing twelve-month figure through Apr 2026 stood at $3.1 million (down 28.65% YoY), and the FY2026 full-year result was $2.8 million, down 35.27% from the prior year.
• Research & Development fell to $476205.0 in Q2 2026 per HSCS's latest filing, from $727026.0 in the prior quarter.
• Across five years, Research & Development topped out at $1.4 million in Q2 2022 and bottomed at $434198.0 in Q3 2022.
• Historically, Research & Development has averaged $822388.8 across 5 years, with a median of $757303.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Research & Development tumbled 60.58% in 2023, then soared 116.56% in 2024.
• Over 5 years, Research & Development stood at $848976.0 in 2022, then retreated by 10.8% to $757303.0 in 2023, then surged by 58.32% to $1.2 million in 2024, then slumped by 39.36% to $727026.0 in 2025, then tumbled by 34.5% to $476205.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $476205.0, $727026.0, and $997206.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.